Eli Lilly buys Calytrix Bio for up to $1.5 billion
Eli Lilly agreed to pay up to $1.5 billion for Calytrix Bio, a biotech developing treatments for myeloproliferative neoplasms like myelofibrosis and essential thrombocythemia.
- Field
- business and funding
- What they did
- Eli Lilly acquired startup Calytrix Bio for up to $1.5 billion to gain access to its development of treatments for rare blood cancers.
- Why it matters
- The acquisition aims to expand the company's biotech portfolio, as the startup is developing therapies for conditions where the body overproduces red blood cells.
#lilly#calytrix#myeloproliferative neoplasms#myelofibrosis#biotech acquisition



